BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  MacroGenic Scores $900M Checkpoint PD-1 R&D Deal With Incyte

  Incyte picked up MGA012 and the exclusive rights to develop the drug worldwide.

  October 25, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  The Medicines Company Slashes Hundreds of Jobs in Restructuring

  In addition to the layoffs, the company is also looking to divest its Infectious Disease Business.

  October 25, 2017

   · 

  2 min read

   · 

  Mark Terry
• Drug Development

  Aldeyra Therapeutics Presents Evidence for Aldehyde Sequestration as a Potential Therapeutic Approach in Succinic Semialdehyde Dehydrogenase Deficiency at the American Society of Human Genetics 2017 Annual Meeting

  Aldeyra Therapeutics presented novel data at the American Society of Human Genetics 2017 Annual Meeting demonstrating that ADX-102 reduced levels of gamma-hydroxybutyrate (GHB) and gamma-aminobutyrate (GABA) in a knockout mouse model of Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency.

  October 25, 2017

   · 

  6 min read
• 

  Business

  Why Even Spinraza Can’t Save Biogen’s Incoming MS Meltdown

  Biogen released its third-quarter financials yesterday, showing total revenues of $3.1B for the quarter, a 4 percent gain compared to the same period the previous year.

  October 25, 2017

   · 

  4 min read

   · 

  Mark Terry
• 

  Deals

  VEXIM Acquired by Stryker in EUR 183M Deal

  Stryker picked up controlling interest in Vexim, a French medical device company that specializes in the minimally invasive treatment of vertebral fractures.

  October 25, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Bay Area’s Five Prime Promotes COO to CEO, Effective January 1, 2018

  After four months of looking, Five Prime Therapeutics has found its new CEO.

  October 25, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  Ablynx Banks $200M IPO in Nasdaq Debut

  Ablynx announced the price of its U.S. IPO at $17.50.

  October 25, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Biotech Bay

  Investors May be Overlooking This Small, Fast-Growing Bay Area Biotech

  You’ve probably heard those advertisements for “the power of protein,” referring to the addition of enzymes to detergent.

  October 25, 2017

   · 

  2 min read

   · 

  Mark Terry
• Biotech Bay

  Sunesis Announces Pricing of $20M Offering of Securities

  These offerings are expected to close on or about October 27, 2017, subject to customary closing conditions.

  October 25, 2017

   · 

  4 min read
• 

  Genetown

  This Massachusetts Marijuana Biotech is Betting the Farm on One Single Drug

  Corbus’ stock popped on the release of topline results from a midstage study involving its lead (and only) clinical drug, anabasum.

  October 25, 2017

   · 

  1 min read